✦ LIBER ✦

Hepatitis B e Antigen Seroconversion After Lamivudine Therapy Is Not Durable in Patients With Chronic Hepatitis B in Korea

✍ Scribed by Byung-Cheol Song; Dong Jin Suh; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee

Book ID: 111721144
Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 126 KB
Volume: 32
Category: Article
ISSN: 0270-9139
DOI: 10.1053/jhep.2000.16665

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Extended lamivudine treatment in patient

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy

✍ Nancy W.Y. Leung; Ching-Lung Lai; Ting-Tsung Chang; Richard Guan; Chuan-Mo Lee; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB

Pretherapy alanine transaminase level as

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B

✍ Rong-Nan Chien; Yun-Fan Liaw; Mark Atkins 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

A higher alanine aminotransferase level

A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients

✍ Tai-Chung Tseng; Chun-Jen Liu; Chia-Chi Wang; Pei-Jer Chen; Ming-Yang Lai; Jia-H 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Adefovir dipivoxil added to ongoing lami

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B

✍ T. Vassiliadis; N. Nikolaidis; O. Giouleme; K. Tziomalos; N. Grammatikos; K. Pat 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Clevudine is highly efficacious in hepat

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

✍ Byung Chul Yoo; Ju Hyun Kim; Tae-Hun Kim; Kwang Cheol Koh; Soon-Ho Um; Young Soo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB 👁 1 views

Clevudine is a pyrimidine analog with potent and sustained antiviral activity against HBV. In the present study, we evaluated the safety and efficacy of clevudine 30 mg daily for 24 weeks and assessed the durability of antiviral response for 24 weeks after cessation of dosing in hepatitis B e antige